SCHEMBL23850484

SCHEMBL23850484

Cc1nnc(-c2ccc(N3CCCCC3)c(N)c2)o1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.65
MAPT P10636 3/20 0.65
S100B P04271 1/20 0.48
MAPK14 Q16539 2/20 0.47
GAA P10253 5/20 0.46
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.43
HRH3 Q9Y5N1 1/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KEAP1 Q14145 1/20 0.41
MEN1 O00255 2/20 0.40
THRB P10828 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31587612 1.00 RAB9A (0.65) RAB9AMAPTS100BMAPK14GAA
SCHEMBL23851060 0.79 MAPT (1.00) RAB9AMAPTGAAALDH1A1HTT
SCHEMBL31587825 0.79 MAPT (1.00) RAB9AMAPTGAAALDH1A1HTT
SCHEMBL15117089 0.77 RAB9A (0.55) RAB9AMAPTMAPK14GAAKDM4E
SCHEMBL30622234 0.77 MAPT (0.56) RAB9AMAPTMAPK14GAAKDM4E
SCHEMBL23850702 0.77 NOTUM (0.61) RAB9AMAPTS100BGAAKDM4E
SCHEMBL31587907 0.77 NOTUM (0.61) RAB9AMAPTS100BGAAKDM4E
SCHEMBL29133205 0.77 MAPT (0.56) RAB9AMAPTMAPK14GAAKDM4E
SCHEMBL1026006 0.75 NPC1 (0.49) RAB9AMAPK14KDM4EALDH1A1HTT
SCHEMBL23850847 0.74 S100B (0.49) RAB9AMAPTS100BGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
EP-3883650-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2021-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 RAB9A 155/4885MAPT 4705/4885S100B 2836/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR RAB9A 204/4885MAPT 302/4885S100B 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.